Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 26, 2015OncotargetOpen Access

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHui LyuThe Fourth People's Hospital of Zibo CityXYXiao He YangSESusan M. EdgertonUniversity of Colorado Cancer Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lyu et al. (2015) studied this question.

synapsesocial.com/papers/6ab49db4187709e8e94ddbb7https://doi.org/10.18632/oncotarget.6404
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metformin induces unique biological and molecular responses in triple negative breast cancer cells2009 · 394 citations
  2. 2Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib2010 · 336 citations
  3. 3Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications2012 · 390 citations
  4. 4Trastuzumab — Mechanism of Action and Use in Clinical Practice2007 · 2,600 citations
  5. 5Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling2007 · 265 citations